Sanofi and Abbott Laboratories are partnering to integrate glucose sensing and insulin delivery technologies for diabetes management.
![]() |
The companies said the non-exclusive collaboration will initially enable data sharing, with the user's consent, between Abbott's FreeStyle Libre mobile application — which enables users to view their real-time glucose levels — and cloud software and the French pharmaceutical giant's connected insulin pens, applications and cloud software, which are being developed.
Sanofi is working to provide connected pens, applications and cloud services that will be compatible with the Abbott Park, Ill.-based medical device maker's FreeStyle Libre system — a sensor-based glucose monitoring system — and other digital health tools.
The data sharing will help patients and doctors in making better-informed treatment decisions around medication, nutrition and lifestyle.
The companies said in a Sept. 16 press release that they plan to bring the integrated services to patients in the next few years, pending regulatory approvals.

